Javier Pinilla, MD, PhD

Articles

Factors That Influence Treatment Decisions in Later-Line CML

December 18th 2024

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.

Implications of the FDA Approval of Asciminib for Newly Diagnosed, Ph+ CP-CML

December 18th 2024

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.

Highlights in MPNs, CLL With Drs Prithviraj Bose and Javier Pinilla Ibarz

December 9th 2024

Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, and Javier Pinilla Ibarz, MD, PhD, of Moffitt Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest in myeloproliferative neoplasms and chronic lymphocytic leukemia, respectively, from the 2024 ASH Annual Meeting.

Future Perspectives on the Treatment Landscape for CLL

February 16th 2024

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in CLL.

Expert Insights into Investigation Therapies for CLL

February 16th 2024

Expert oncologists explore emerging therapies being investigated in CLL, including BTKi degraders, CAR-T therapy, and bispecific antibodies, and discussed their potential impact in shaping the future of CLL treatment.

Emerging Data Surrounding Mechanisms of Resistance to Non-Covalent BTKis

February 9th 2024

The expert panel discusses recent data regarding the mechanisms of resistance to non-covalent BTK inhibitors in CLL.

Role of Non-Covalent BTKis in R/R CLL: Updates from Ongoing BRUIN and Bellwave Trials

February 9th 2024

Jacqueline Barrientos, MD, MS, discusses the role of non-covalent BTK inhibitors in R/R CLL and provided concise comments on the latest data, including insights from the ongoing BRUIN and Bellwave trials.

Treatment Resistance with Covalent BTKis: Translating Data into Clinical Practice

February 2nd 2024

Javier Pinilla, MD, PhD explores evidence on molecular mechanisms leading to resistance in second-generation BTK inhibitors for CLL, providing insights from recently presented data at ASH 2023.

Expert Insights into Navigating Cardiovascular Risks with BTKi Therapy

February 2nd 2024

A panel of expert oncologists explore the influence of hypertension risk and other cardiovascular AEs in guiding treatment selection with BTKis, sharing insights from ASH 2023.

Expert Perspectives on Navigating Treatment Selection with BTKis in CLL

January 26th 2024

Faculty provide insights into the selection of BTK inhibitors, emphasizing the role of efficacy, toxicity, and quality of life data in treatment decisions, and exploring the impact of MAIC data.

Navigating BTKi Therapy in R/R CLL: Updates from ELEVATE-RR and ALPINE

January 26th 2024

Panel experts examine considerations for BTKi-based strategies in R/R CLL, highlighting pivotal findings from head-to-head trials, including acalabrutinib vs ibrutinib in ELEVATE-RR and zanubrutinib vs ibrutinib in ALPINE, covering safety, quality of life, and extended follow-up data.

Treatment Sequencing Strategies for R/R CLL: Impact of Prior 1L Therapy

January 19th 2024

Faculty share insights into the overall strategy for managing relapsed/refractory CLL following first-line therapy with venetoclax-based regimens and BTK inhibitors, discussing strategy variations based on prior first-line treatments.

Exploring the Role of BTKi-Based Combination Therapies for Front-line Management of CLL

January 19th 2024

Experts explore the role of BTKi-based combination therapy in the front-line treatment of CLL, focusing on patient considerations and referencing key data from CAPTIVATE, FLAIR, MAJIC, and SEQUOIA (Arm D).

Impact of Off-Target AEs and Treatment Resistance on Evolving 1L Therapy Strategies for CLL

January 12th 2024

Javier Pinilla, MD, PhD, provides a brief overview of the changing CLL treatment landscape, discussing the influence of off-target adverse events and the development of treatment resistance on the evolution of BTK inhibitor therapy.

Strategies for Managing Treatment-Naïve CLL with High-Risk Features

January 12th 2024

Joanna Rhodes, MD, MSCE, explores the general approach to treatment-naïve CLL patients with high-risk factors such as del17p and TP53 mutations.

Exploring BTKi Monotherapy in CLL: Long-Term Updates from ELEVATE-TN and SEQUOIA

January 12th 2024

Brian Hill, MD, PhD, discusses the use of BTK inhibitor monotherapy in CLL and presented recent long-term data updates from studies such as the 6-year follow-up of ELEVATE-TN and the extended follow-up from SEQUOIA.

Current Front-Line Treatment Options for CLL in 2023

December 19th 2023

Catherine Coombs, MD discusses the present CLL front-line treatment landscape, addressing considerations like choosing fixed-duration or continuous therapy and variations in first-line approaches based on age and ECOG status.

Dr. Pinilla-Ibarz on Choosing Second-line BTK Inhibitors in CLL

October 5th 2022

Javier Pinilla-Ibarz, MD, PhD, discusses the factors that go into choosing the optimal second-line BTK inhibitors for patients with chronic lymphocytic leukemia.

Dr. Pinilla-Ibarz on Ibrutinib's Efficacy in Treating High-Risk Patients With CLL

June 13th 2017

Javier Pinilla-Ibarz, MD, PhD, associate member, Malignant Hematology and Immunology Program at the H. Lee Moffitt Cancer Center, discusses the outcomes of patients with high-risk chronic lymphocytic leukemia (CLL) and how ibrutinib (Imbruvica) targets these patients.